UroGen Pharma Ltd (URGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, UroGen Pharma Ltd (URGN) has a cash flow conversion efficiency ratio of 0.365x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-45.32 Million) by net assets ($-124.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See UroGen Pharma Ltd (URGN) net asset quality to measure how much of total assets are equity-financed.
UroGen Pharma Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how UroGen Pharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check URGN operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
UroGen Pharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of UroGen Pharma Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jangho Group Co Ltd
SHG:601886
|
0.043x |
|
Redfin Corp
NASDAQ:RDFN
|
-0.240x |
|
Shenzhen Bluetrum Technology Co. Ltd. A
SHG:688332
|
N/A |
|
Exail Technologies S.A.
PA:EXA
|
0.102x |
|
Bright Dairy & Food Co Ltd
SHG:600597
|
0.044x |
|
Tennant Company
NYSE:TNC
|
-0.059x |
|
Jinlongyu Group Co Ltd Class A
SHE:002882
|
0.066x |
|
Magellan Aerospace Corporation
TO:MAL
|
-0.002x |
Annual Cash Flow Conversion Efficiency for UroGen Pharma Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of UroGen Pharma Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see how much is UroGen Pharma Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-105.47 Million | $-162.44 Million | 1.540x | -85.99% |
| 2024-12-31 | $-8.80 Million | $-96.77 Million | 10.992x | +838.56% |
| 2023-12-31 | $-65.21 Million | $-76.38 Million | 1.171x | +19.53% |
| 2022-12-31 | $-89.36 Million | $-87.56 Million | 0.980x | +109.71% |
| 2021-12-31 | $8.41 Million | $-84.89 Million | -10.091x | -818.23% |
| 2020-12-31 | $96.36 Million | $-105.89 Million | -1.099x | -179.00% |
| 2019-12-31 | $180.30 Million | $-71.02 Million | -0.394x | +4.95% |
| 2018-12-31 | $90.09 Million | $-37.33 Million | -0.414x | -196.64% |
| 2017-12-31 | $68.52 Million | $-9.57 Million | -0.140x | -154.38% |
| 2016-12-31 | $16.31 Million | $4.19 Million | 0.257x | +161.41% |
| 2015-12-31 | $17.15 Million | $-7.17 Million | -0.418x | +64.76% |
| 2014-12-31 | $3.47 Million | $-4.12 Million | -1.187x | -27.26% |
| 2013-12-31 | $2.74 Million | $-2.56 Million | -0.933x | -- |
About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder… Read more